Powered by

Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection; Proceeds will accelerate ongoing FDA registrational study of company's first blood test for colorectal cancer screening and adva

Aug 26, 2020 - Business Wire
Board and Executive Moves-Investments

Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced an oversubscribed $270 million Series C financing, bringing the company's total financing to over $500 million since the company's launch. The proceeds will be used to accelerate the PREEMPT CRC(TM) clinical trial for Freenome's blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of bl...